Cross-Sector entity

Healius

Company HLS
5

pharma is the sole category represented across all 1 tracked stories. Healius is most often covered alongside Lumus Imaging, which appears in 1 of these 1 story. Each carries 6 original sources on average. We currently track 1 Cross-Sector story that mention Healius, all published on February 18, 2026.

1 verified story tracked

Last mentioned: Feb 18, 2026

Entity pulse

Recent coverage · Healius

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Healius

pharma is the sole category represented across all 1 tracked stories. Healius is most often covered alongside Lumus Imaging, which appears in 1 of these 1 story. Each carries 6 original sources on average. We currently track 1 Cross-Sector story that mention Healius, all published on February 18, 2026.

Stories tracked
1
Sources per story
6

Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Healius. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning Healius 1

Biotech pharma Neutral 5

Healius H1 Earnings: Diagnostic Resilience Meets Margin Headwinds

Healius's H1 earnings call highlighted a strategic focus on operational efficiency and pathology volume recovery in a challenging macroeconomic environment. As the diagnostic giant navigates rising labor costs and inflationary pressures, its performance serves as a critical indicator for the broader Australian healthcare services sector.

6 sources